$14.27
arrow_drop_up0.03%Key Stats | |
---|---|
Open | $14.27 |
Prev. Close | $14.26 |
EPS | -0.09 |
Dividend | Non-Dividend |
Next Earnings Date | - |
Dividend Yield % | - |
PE Ratio | - |
LOW | HIGH | |
---|---|---|
Day Range | 14.26 | 14.27 |
52 Week Range | 8.87 | 15.12 |
Ratios | |
---|---|
EPS | -0.09 |
Don't miss out on the opportunity to stay ahead in the ever-changing world of finance.
Period: Next 12 Months
•Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.
Healthcare Revenue Cycle Management Market Size to Achieve USD 453.47 Bn by 2034
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates RCM, ESGR on Behalf of Shareholders
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Revance Therapeutics, Inc. (Nasdaq – RVNC), Greenbrook TMS, Inc. (OTC – GBNHF), R1 RCM Inc. (Nasdaq - RCM), Enstar Group Limited (Nasdaq – ESGR)
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: R1 RCM Inc. (Nasdaq - RCM), Enstar Group Limited (Nasdaq – ESGR), Premier Financial Corp. (Nasdaq – PFC), The First Bancshares, Inc. (NYSE – FBMS)
RCM Alert: Monsey Firm of Wohl & Fruchter Investigating Fairness of the Sale of R1 RCM to TowerBrook Capital Partners and Clayton, Dubilier & Rice
Unveiling 8 Analyst Insights On R1 RCM - Benzinga